Covid-19 Pandemic
 Kamala Harris says she won’t take Trump’s word on vaccine France leads Europe’s virus surge just as schools reopenAustralia’s virus epicenter plans to ease its lockdown rules A widening testing crisis By now it’s well-known that shortages of key supplies have hamstrung Covid-19 testing in the U.S. But the same outages are also limiting testing for other illnesses, like urinary tract infections, gonorrhea and lung pathogens in patients with cystic fibrosis. This new trend was shaped by a months-long focus on ramping up Covid testing: Manufacturers say that with most medical care interrupted, they prioritized Covid-related supplies. And yet “the impact of this supply chain is much, much greater than if we can’t get our Covid tests in 24 hours,” says Melissa Miller, who directs the clinical and molecular microbiology labs at UNC Medical Center in Chapel Hill, North Carolina. Individual patients now may have to accept longer waits for results and less frequent testing. And it raises bigger-picture risks, like doctors missing disease-causing pathogens or turning to broad-spectrum antibiotics more often, which can foster antibiotic resistance. The episode highlights something doctors worry about: that our longstanding emphasis on the new coronavirus comes at the cost of other diseases. The implications of that will likely keep emerging for some time.— Emma Court Track the virus Vaccine Leaders Brace for Their Moment of Truth Drugmakers made big promises for a quick turnaround on coronavirus vaccines. The moment of truth for the front-runners is coming as soon as this month.  The first results showing whether a vaccine can stop people from getting the virus could come by mid-September from AstraZeneca Plc, according to Airfinity Ltd., an analytics company that tracks drug trials. Two other contenders — the U.S.’s Moderna Inc. and the U.S.-German partnership of Pfizer Inc. and BioNTech SE — may also have initial data before a key Food and Drug Administration meeting on virus vaccines scheduled for Oct. 22, Airfinity said. The federal government has told states to prepare for a vaccine by Nov. 1. Sponsored Content by Siemens America’s factories, power plants, transportation and hospitals all need technology and our technology is only as powerful as the people deploying and maintaining it. Keeping America moving takes more than technology alone. It takes a human touch. Siemens Ingenuity for life. What you should read FDA Promises Transparency in Vaccine Review Commissioner Hahn responds to questions on how shots will be approved. African Union Seeks to Speed Border Reopenings Mobile app gives latest rules on testing and lockdown across the region. Heat Wave Brings Crowds to California Beaches Health officials warn they may be forced to shut public spaces. Virus Tests Cut UFC Bouts in Las Vegas Positive readings for virus left the shortest list of fights since 2005. Pandemic Heightens Appetite for Luxury Assets A New York-startup allows investors to buy a share of famous works. Know someone else who would like this newsletter? Have them sign up here. Have any questions, concerns, or news tips on Covid-19 news? Get in touch or help us cover the story. Like this newsletter? Subscribe for unlimited access to trusted, data-based journalism in 120 countries around the world and gain expert analysis from exclusive daily newsletters, The Bloomberg Open and The Bloomberg Close . Follow Us Get the newsletter You received this message because you are subscribed to Bloomberg’s Coronavirus Daily newsletter. Unsubscribe | Bloomberg.com | Contact Us Bloomberg L.P. 731 Lexington, New York, NY, 10022 |
PreviousCovid-19 Pandemic